Medical stent

Information

  • Patent Grant
  • 7951206
  • Patent Number
    7,951,206
  • Date Filed
    Monday, November 5, 2007
    17 years ago
  • Date Issued
    Tuesday, May 31, 2011
    14 years ago
Abstract
A medical stent is sized for placement in a ureter. The stent includes a first section which includes a first material, defines a lumen, and includes a first coil completing at least one revolution. A second section of the stent includes a second material, defines a lumen, and includes a second coil completing at least one revolution. A third section defines a lumen and is located between the first and second sections. The third section includes a co-extrusion of the first and second materials. One of the first or second sections is harder than the other section.
Description
TECHNICAL FIELD

The present invention relates to medical stents and related methods. More specifically, the invention relates to medical stents having one end section which is softer than a section at the other end of the stent.


BACKGROUND INFORMATION

Fluid sometimes needs to be drained from a body. For example, urine formed in one or both kidneys might need to be drained into the bladder. One way to accomplish such drainage is to use a medical device that conveys the fluid (e.g., urine) through a lumen. Such devices include stents and catheters. Existing stents can be uncomfortable for the patient, especially when they reside in the ureter between the kidney and the bladder, or can be difficult for a medical professional to place in a patient.


SUMMARY OF THE INVENTION

The present invention provides medical stents for facilitating drainage of fluid and methods for placing such stents. For example, such stents can be placed in a ureter to facilitate drainage of fluid from a patient's kidney to a patient's bladder. Generally, stents according to the invention have a “softer” end and a “harder” end. The harder end generally resides in the patient's kidney while the softer end generally resides in the patient's bladder. The harder end transitions to the softer end in a transition section produced by a co-extrusion process where deposition of a first material is gradually ceased and deposition of a second is gradually increased. The harder end is suited to retain the stent in the patient's kidney and/or facilitate placement in a patient while the softer end is suited to increase patient comfort and/or, to a degree, retain the stent in the patient's bladder. Such stents also are useful in other situations such as biliary drainage or, generally, where one body structure is drained to another body structure.


In one embodiment, a medical stent includes a single-piece, extruded stent body which does not substantially soften when exposed to a temperature of a human body. At least a portion of the stent body can be sized for placement in a ureter, and at least a section of the stent body can define holes therethrough. The stent body itself includes a first section, a second section, and a third section defining a lumen and located between the first and second sections. The first section includes a first material having a first durometer value while the second section includes a second material having a second durometer value. The second durometer value is greater than the first durometer value. The third section includes a co-extrusion of the first and second materials that is disposed between the first coil and the second coil. The first section defines a lumen and includes a first coil completing at least one revolution, and the second section defines a lumen and includes a second coil completing at least one revolution. An outer surface of the third section smoothly transitions to outer surfaces of the first and second sections immediately proximate the third section, and an inner diameter of the third section is substantially constant through the third section and on either side of the third section immediately proximate to the third section in the first and second sections.


The embodiment described above, or those described below, can have any of the following features. The first material can include ethylene vinyl acetate. The stent body can include a mark on an outer surface of the stent body. The stent body can include a radiopaque marking. The stent can have an outer diameter of about 4 French to about 9 French. The stent can have an inner diameter of about 0.38 inches. The stent can have a length of about 10 cm to about 30 cm as measured between the coils. The stent can include a hydrophilic coating. The first material can have a durometer value of about 70 to about 90 on a Shore A scale. The second material can have a durometer value of about 80 to about 95 on a Shore A scale. At least one of the coils can be asymmetric. An end of at least one of the first section and the second section can be tapered. A cross-section of the lumen in at least one of the first, second, and third sections can be circular. A cross-section of at least one of the first, second, and third sections can be circular. At least one of the first, second, and third section can include a radiopaque material.


In another embodiment, a medical stent includes a single-piece, extruded stent body which does not substantially soften when exposed to a temperature of a human body. At least a portion of the stent body can be sized for placement in a ureter, and at least a section of the stent body can define holes therethrough. The stent body itself includes a first section, a second section, and a third section defining a lumen and located between the first and second sections. The first section defines a lumen and includes a first coil completing at least one revolution, and the second section defines a lumen and includes a second coil completing at least one revolution. The first section includes a first material, and the second section includes a second material. The first coil has a first retention strength, and the second coil has a second retention strength. The second retention strength is greater than the first retention strength. The third section includes a co-extrusion of the first and second materials that is disposed between the first coil and the second coil. An outer surface of the third section smoothly transitions to outer surfaces of the first and second sections immediately proximate the third section. An inner diameter of the third section is substantially constant through the third section and on either side of the third section immediately proximate to the third section in the first and second sections.


In another aspect of the invention, a method for placing a medical stent includes inserting a medial stent, including any of the stents described above or below with any of the features described above or below, into a ureter.





BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating principles of the invention.



FIG. 1 is a schematic rendering of a stent according to the invention.



FIG. 2 is a schematic end-on view of the stent of FIG. 1.



FIG. 3 is a schematic rendering of the stent of FIG. 1 in a kidney, ureter, and bladder.



FIG. 4 is an image of a cross section of the embodiment of FIG. 1 taken along section line 4-4.



FIG. 5 is an image of a cross section of the embodiment of FIG. 1 taken along section line 5-5.



FIG. 6 is an image of a cross section of the embodiment of FIG. 1 taken along section line 6-6.



FIG. 7 is an image of a cross section of the embodiment of FIG. 1 taken along section line 7-7.



FIG. 8 is an image of a cross section of the embodiment of FIG. 1 taken along section line 8-8.



FIG. 9 is a schematic rendering of one embodiment of a stent according to the invention.



FIG. 10 is a table containing renal coil retention strength values.



FIG. 11 is a table containing inner and outer diameter sizes for certain embodiments of the invention.



FIG. 12 is a schematic rendering of one system used to manufacture stents according to the invention.





DESCRIPTION

The present invention provides medical stents for facilitating drainage of fluid and methods for placing such stents. For example, such stents are placed in a ureter to facilitate drainage of fluid from a patient's kidney to a patient's bladder. Generally, stents according to the invention have a “softer” end and a “harder” end. The harder end generally resides in the patient's kidney while the softer end generally resides in the patient's bladder. The harder end transitions to the softer end in a transition section produced by a co-extrusion process where deposition of a first material is gradually ceased and deposition of a second is gradually increased. As used herein, the terms “hard” and “soft,” and various grammatical forms thereof, are general terms meant to generally refer to a difference in properties, including, but not limited to, a difference in the durometer value of all or some of the material(s) used to construct a stent (for example, a higher durometer value of one material used in constructing a section of a stent (even if other materials are also used to construct that same section of stent) can mean “hard” and a lower durometer value of one material used in constructing another section of a stent (even if other materials are also used to construct that same section of stent) can mean “soft”), a difference in the retention strengths of the coils on either end of a stent (for example, a higher retention strength can mean “hard” and a lower retention strength can mean “soft”), a difference in stiffness (for example, a more stiff material/section of stent can be “hard” and a less stiff material/section of stent can be “soft”), or other differences between material(s) used to construct a stent or between sections of a stent that those skilled in the art would consider “hard” and/or “soft.”


On the one hand, some ureteral stents that are in use are made from a higher durometer material to facilitate placement and retention in the body. However, these firmer stents may contribute to some patient discomfort issues. On the other hand, some ureteral stents that are in use are made from a lower durometer material in an effort to enhance patient comfort. However, these softer stents may be difficult to place and may migrate once placed in the patient's body.


In contrast, stents according to the invention have a harder end at one end and a softer end at the other end. This construction is desirable because the harder end is suited for placing the stent in the patient's kidney and/or to retain the stent in the patient's kidney while the softer end is suited to increase patient comfort and/or, to a degree, retain the stent in the patient's bladder. Accordingly, stents according to the invention are designed to incorporate multiple desirable features into a single stent.


Referring to FIGS. 1 and 2, a schematic representation of one embodiment of a stent 10 according to the invention is shown. Generally, the stent 10 has three sections 20, 22, 24. A first section 24 is located at the proximal end (as used herein, proximal refers to the end of a stent closest a medical professional when placing a stent in a patient) of the stent 10. A second section 20 is located at the distal end (as used herein, distal refers to the end of a stent furthest from a medical professional when placing a stent in a patient) of the stent 10. A third section 22 is located between the first 24 and second sections 20. The location of the sections 20, 22, 24 as shown in FIG. 1 is approximate, emphasis instead being placed on illustrating the principles of the invention. The first section 24 has a first coil 14 that makes more than one revolution. The first coil 14 is offset from the general axis of the stent 10 (best seen in FIG. 2). The second section 20 has a second coil 12 which also makes more than one revolution and also is offset from the general axis of the stent 10. The second coil 12 has a tapered tip (which, in certain embodiments, can be relatively long). Additionally, or in the alternative, the tip can be beveled. Holes 16 (only some of the holes are labeled) in the outer surface of the stent 10 are located along the length of stent 10. These holes 16 allow the outside environment to communicate with a lumen inside the stent 10. The holes 16 can be placed in many configurations, one of which is shown in FIG. 1. In alternate embodiments, holes can be placed along a section or sections of a stent. Additionally, a suture 18 is attached to the first section 24 and is used for placing the stent 10 in a desired position as well as removing the stent 10.


The third section 22 is formed from a coextrusion of the material(s) from which the first section 24 is made and the material(s) from which the second section 20 is made. As shown in FIG. 1, the third section 22 is closer to the first coil 14 than to the second coil 12. However, in alternative embodiments, the third section (i.e., a transition section where the material(s) making up one section of the stent transition to the material(s) making up another section of the stent) can be located anywhere along the length of the stent. The transition section typically is located between the coils on either end of the stent and is about 2 cm long to about 10 cm long. However, the transition section can be any length. The first section 24 includes a first material having a first durometer. The second section 20 includes a second material having a second durometer, which is greater than the first durometer value. Accordingly, the first section is “softer” than the second section. The third section 24 includes both the first and second materials, and the first and second materials are separate, distinct, and associated in an unsymmetrical, irregular configuration. In operation, the first coil 14 typically resides in the patient's bladder, and the second coil 12 typically resides in the patient's kidney (FIG. 3).


The stent 10 is a single piece and is sized to fit within a ureter. For example, two types of ethylene vinyl acetate (“EVA”) can be extruded to form the stent. In a continuous process, the first section 24 is formed from one type of EVA; a transition section (i.e., the third section 22), then, is formed by gradually ceasing the deposition of the first type of EVA and gradually increasing the deposition of a second type of EVA; and the other end of the stent, the second section 20, is formed from the second type of EVA after the first type of EVA has ceased being extruded. Each type of EVA has a different durometer value, with the first type of EVA having a durometer value that is less than the durometer value of the second type of EVA. The two materials in the third section 22 are separate, are distinct, and are associated with each other in an irregular configuration. Additionally, other materials may be mixed with the first and/or second types of the EVA prior to extrusion. For example, radiopaque materials, such as bismuth subcarbonate, and/or colorants can be added. The addition can occur at the site of manufacture or a supplier can supply the EVA already compounded with the radiopaque material alone or with the colorant alone or with both the radiopaque material and the colorant. Even if these materials are mixed, the fact that one EVA type has a durometer value less than the second EVA type can mean that the section of the stent formed from the first type of EVA is “softer” than the section of the stent formed from the second type of EVA.


After extrusion, the curled portions are formed. For example, the extrusion can be placed on a mandrel, shaped in a particular form, and the extrusion can be formed into a desired shape by heating the extrusion while on the mandrel. Alternatively, the extrusion can be laid into a plate having a groove cut into it in the shape of the desired final product. The plate is heated from below (for example, with a heat lamp) to form the extrusion into a shape according to the configuration of the groove. Both coils can be formed at the same time using two adjacent plates, each with a groove for the coil at either end of the stent. The plates are heated at different temperatures, to the extent necessary, for example, if the two ends of the stent are made from different material(s), and can be heated for the same length of time. Additionally, after extrusion, holes can be bored into the stent by placing a nylon core inside the stent to prevent the stent from collapsing and drilling through the stent, for example, with a hollow sharpened bit.



FIGS. 4-8 show a series of cross-sectional views taken along the length of one of the stent 10. The approximate position of these cross-sections are shown in FIG. 1. It should be understood that the position of these cross-sections is merely an example. In various embodiments, the transition section of the medical stent can be relatively short, or relatively long, depending upon the physical characteristics of the stent that are desired. Additionally, sections taken in various embodiments may look different than the representations shown in FIGS. 4-8, depending upon, for example, the length of the transition section, the materials being extruded, and the method of co-extrusion used to manufacture the stent. Thus, the cross-sections shown in FIG. 1 and FIGS. 4-8 should be understood to illustrate both one embodiment of the invention and the general principle whereby the material(s) forming one section of the stent transition to the material(s) forming the other section of the stent. These figures show one material mixed with a colorant (for example, EVA and a colorant) (the darker portions of the cross-section) gradually increasing in abundance along the length of at least part of the stent and a second material not mixed with a colorant (for example, a second type of EVA) (the lighter portions of the cross-section) gradually decreasing in abundance along the length of at least part of the stent. Some of these views are indicative of the first and second materials being separate, distinct, and associating in an unsymmetrical, irregular configuration. In certain embodiments, the change in material composition can occur over any part of the shaft of the stent or all of the shaft of the stent. At least one of the materials can be ethylene vinyl acetate. Additionally, stents according to the invention can have several transition zones where materials change and/or can have more than two materials (or more than two mixtures of materials) that change along the length of the stent. For example, the shaft of a stent, or a portion thereof, may or may not be the same material(s) and/or the same durometer as either of the two coils. Moreover, each of the shaft and two coils can be formed from different material(s).


In certain embodiments, the material(s) that make up the second section of the stent (the harder section of the stent) can extend at least half way down the shaft of the stent, and can extend even further, such that the transition section (e.g., the third section in FIG. 1) is closer to the first coil (the coil in the softer section of the stent) than to the second coil (the coil in the harder section of the stent). Such a configuration enhances the placement characteristics of a stent because the preponderance of hard material(s) makes the stent stiffer and easier for a medical profession to place. In many embodiments, the transition of material(s) does not occur in one of the coils such that each coil is formed from a single material (or a single mixture of materials). However, the transition can occur anywhere along the length of the stent. Also in some embodiments, the inner diameter of the stent is maximized but not so much as to adversely impact the stent's ability to be pushed over a guidewire.


Interrupted layer extrusion techniques, gradient-type coextrusion techniques, or similar techniques can be used to produce the transition sections described above. Such extrusion techniques can be used instead of using joints or welds to bring together two ends of a stent, each end having a different physical property than the other end. Such joints or welds can fail during use of the stent and can be difficult to manufacture. Continuous material extrusion according to the invention enhances stent integrity while allowing for desired placement and drainage characteristics. Additionally, continuous extrusion products tend not to kink in the transition zone as might a stent with a butt-joint or a weld. In general, any type of thermoplastic polymer can be extruded such as a silicone, a polyurethane, or a polyolefin copolymer such as EVA. In general, in one embodiment of the invention, two types of EVA (at least one type of EVA can be mixed with a radiopaque material and at least one type of EVA can be mixed with a colorant) are extruded to form the stent. In a continuous process, one end of the stent is formed from one type of EVA (for example, the first section 24 in FIG. 1); a transition section (for example, the third section 22 in FIG. 1), then, is formed by gradually ceasing the deposition of the first type of EVA and gradually increasing the deposition of a second type of EVA; and the other end of the stent is formed from the second type of EVA (for example, the second section 20 in FIG. 1) after the first type of EVA has ceased being extruded. Each type of EVA has a different durometer value. The mixing of the two types of EVA in the transition section produces a section in which the two materials are separate, are distinct, and are associated with each other in an irregular configuration. After extrusion, the curled portions are formed.


In more detail and in one example of an extrusion technique as shown in FIG. 12, a gradient-type technique, a first pelletized type of EVA is placed in a first dryer 50 and a second pelletized type of EVA is placed in a second dryer 60. The dryers 50, 60 are hoppers to contain the pellets, and, to the extent necessary, to dry the pellets, and each dryer 50, 60 feeds the pellets to an extruder 52, 62. The two extruders 52, 62 melt the pellets, and each of the melted materials passes through a separate adapter 54, 64 to a separate melt pump 56, 66 (which are also referred to as a gear pumps). Each melt pump 56, 66 has a rotary gear which allows the melted materials to pass through the pump 56, 66. A computer 58 runs two servo motors 55, 65 that control the melt pumps 56, 66. The computer 58 controls the revolutions per minute as a function of the distance over which a point in the extruded product travels. There is a feedback loop between each melt pump 56, 66 and its related extruder 52, 62 such that when the pressure between the extruder 52, 62 and the melt pump 56, 66 is too high, the extruder 52, 62 shuts off. Each extruder 52, 62 is a slave to its respective melt pump 56, 66. The two separate lines, each containing a different EVA, come together at a cross-head 68. The cross-head 68 contains lumens that are separate from each other except for a relatively short distance in the cross-head 68. This distance is immediately adjacent a die and a tip where the extruded product exits the cross-head 68. The two materials only come together immediately adjacent to the die and the tip. The die dictates the outer diameter of the extruded product and the tip dictates the inner diameter of the product. The end of the tip is flush with the end of the die. Air is metered into a port that connects with the tip. Air from the tip pushes out the outer and inner diameters of the extruded product. Also, the tip is ported to the atmosphere to avoid the extruded product being flat. The extruded product (emerging from the cross-head 68 according to arrow 70) is then cooled in a quench tank 72, which is a water bath, to fix the product's shape. Next, the cooled product is dried with an air blower 74 and is measured with a laser micrometer 76. The laser micrometer 76 measures the outer diameter of the extruded product, and other gauges can be used to measure the inner diameter of the extruded product. The laser micrometer 76 is either monitored by an operator or is connected in a feedback control loop to control the final diameter of the extruded product. After passing through the laser micrometer 76, the extruded product is pulled through a “puller/cutter” machine 78. This device 78 pulls at a particular rate to control the shape of the extruded product, such as tapers on the ends of the extruded product, and cuts the extruded product to the correct length for a stent. Finally, a conveyer 80 separates the acceptable and unacceptable final products. Generally, if the diameter of the extruded product is too large according to the laser micrometer, the operator or the feedback loop will act to speed up the puller/cutter, decrease the extruder(s)/melt pump(s) output(s), and/or decrease the internal air support provided through the tip. If the diameter of the extruded product is too small, the operator or the feedback loop will act to slow down the puller/cutter, increase the extruder(s)/melt pump(s) output(s), and/or increase the internal air support provided through the tip. When the adjustments are made, the measurement of the inside diameter of the extruded product can be taken into account.


This system has at least three features. First, the entire system has no valves, and, specifically, the cross-head 68 has no moving parts such as valves. Second, extrusion can occur in a non-linear fashion, because the computer 58 and servo motors 55, 65 control the melt pumps 56, 66 on the basis of distance traveled. Thus, the melt pumps 56, 66 are “ramped up” or “ramped down” as necessary. Accordingly, a theoretically infinite gradient of material can be extruded by varying the pumping rates of the melt pumps 56, 66. And third, the process for combining the two EVA materials does not involve production of waste melted material as a byproduct of manufacture.


Through this machinery, in a continuous process, one end of the stent is formed from one type of EVA; a transition section, then, is formed by gradually ceasing the deposition of the first type of EVA and gradually increasing the deposition of a second type of EVA; and the other end of the stent is formed from the second type of EVA after the first type of EVA has ceased being extruded. Each type of EVA has a different durometer value. A radiopaque material and/or a colorant can be added to either of the EVA materials (the addition can occur at the site of manufacture or a supplier can supply the EVA already compounded with the radiopaque material, such as bismuth subcarbonate, alone or with the colorant alone or with both the radiopaque material and the colorant). The mixing of the two types of EVA in the transition section results in a section in which the two materials are separate, are distinct, and are associated with each other in an irregular configuration. After extrusion, the curled portions are formed. For example, the extrusion can be placed on a mandrel, shaped in a particular form, and the extrusion can be formed into a desired shape by heating the extrusion while on the mandrel. Alternatively, the extrusion can be laid into a plate having a groove cut into it in the shape of the desired final product. The plate is heated from below (for example, with a heat lamp) to form the extrusion into a shape according to the configuration of the groove. Both coils can be formed at the same time using two adjacent plates, each with a groove for the coil at either end of the stent. The plates are heated at different temperatures, to the extent necessary, for example, if the two ends of the stent are made from different material(s), and can be heated for the same length of time. Additionally, after extrusion, holes can be bored into the stent by placing a nylon core inside the stent to prevent the stent from collapsing and drilling through the stent, for example, with a hollow sharpened bit. The stent also can be covered in part or in its entirety with a lubricant. Useful coatings include those that are hydrophilic.


Various embodiments of medical stents according to the invention can have any of a variety of features. A dual durometer stent that incorporates a higher durometer value material (for example, firm EVA) for the renal coil and that gradually transitions into a lower durometer value material (for example, soft EVA) for the bladder coil is useful. For example, the “hard” material can be EVA having a durometer value of about 80 to about 95 on a Shore A scale, preferably about 87 to about 95 on a Shore A scale, and more preferably about 90 on a Shore A scale, and the “soft” material can be another type of EVA having a durometer value of about 70 to about 90 on a Shore A scale, preferably about 78 to about 90 on a Shore A scale, and more preferably about 86 on a Shore A scale. These values are examples of a more general principle, namely, having a stent with a harder end and a softer end. Other materials or EVA having a durometer value different than that described above can be useful. In some embodiments, the materials forming the stent, such as the two types of EVA, are mixed with other materials. For example, as described above, each type of EVA can be mixed with a radiopaque material, such as bismuth subcarbonate, or a colorant. The radiopaque material allows a medical professional to place the stent under the guidance of an x-ray device and fluoroscope or other similar device where the radiopaque material appears on a view screen because it blocks or reflects x-ray energy. The colorant also can be used as a visual cue to a medical professional about the location of the stent in the patient.


Another way to describe the two ends of the stent are by the coil retention strength of each coil of the stent. For example, such retention strengths can be used as a measure of the ability to resist migration within a patient, or, more broadly, as a measure of how “hard” or how “soft” the ends of the stent are. One way to determine retention strength is found in American Society for Testing and Materials (ASTM) Designation F 1828-97: Standard Specification for Ureteral Stents, approved Nov. 10, 1997, and published May, 1998, the disclosure of which is incorporated herein by reference. This specification covers single-use ureteral stents with retaining means at both ends, during short term use for drainage of urine from the kidney to the bladder. These stents typically have diameters of 3.7 French to 14.0 French, lengths of 8 cm to 30 cm, and are made of silicone, polyurethane, and other polymers. They are provided non-sterile for sterilization and sterile for single-use. It is noted that this ASTM standard excludes long-term, indwelling usage (over thirty days), use of ureteral stents for non-ureteral applications, and non-sterile stents. Nevertheless, even if stents according to the invention meet any of these exclusions, or do not otherwise fall under the scope of this ASTM standard, to the extent those skilled in the art understand it to be reasonable to use the coil retention strength test method described in this document, the test method can be used.


The retention strength test method (section 6.2 of the ASTM document) involves using a funnel block submerged in a water bath at approximately 37 degrees Celsius. The funnel block is a block of TEFLON or DERLIN defining a funnel. The funnel is two inches at its widest diameter and, in cross section, has walls that form an approximately 60 degree angle. The funnel narrows to a bore slightly larger than the specimen to be tested, and this bore is about 0.675 inches long. There must be clearance between the outside diameter of the test specimen and the inside diameter of the hole in the funnel block through which the specimen is pulled. For example, for stents of 3.7 to 8.5 French, a funnel bore should be 0.125 inches (3.16 mm) in diameter; for stents of 10.0 French, a funnel bore should be 0.159 inches (4.04 mm) in diameter; and for stent of 14.0 French, a funnel bore should be 0.210 inches (5.33 mm) in diameter. The test specimen is removed from its sterile packaging, and the retention means (for example, a coil at the end of the stent) of the specimen is straightened with an appropriate guidewire. The test specimen is soaked for at least thirty days and is cut to allow a straight portion of the stent to be inserted upwards through the funnel fixture into the grip of a tensile test machine without loading the retention mechanism of the stent to be tested. Prior to inserting the test specimen, the test specimen is submerged in the water bath for at least one minute to allow it to reach thermal equilibrium. If the material is significantly effected by moisture, the test specimen should be allowed to equilibrate for a minimum of 24 hours. The straight portion of the stent then is inserted through the bottom of the funnel and into the grip. If testing 30 days after opening the package, the retention means is not straightened prior to testing. Then, the specimen is pulled up through the funnel at 20 inches/minute. The maximum force required to pull the stent completely through the funnel is recorded.


Referring to FIG. 10, a table is provided that compares one stent embodiment according to the invention to other stents. The retention strength of the renal coil (for example, but without limitation, the second coil 12 in FIG. 1) for the various stents in various sizes is determined using the test method described above. The bladder coil (for example, but without limitation, the first coil 14 in FIG. 1) retention strength of the embodiment of the invention described in FIG. 10 would be less than or equal to the renal coil strength provided in FIG. 10. In one embodiment, the retention strength of the bladder coil approximates those values provided in FIG. 10 for the Contour™ stent. These values are examples and are not limiting. Other retention strengths are possible, depending upon the method of manufacture or other considerations. However, typically, retention strengths of the two coils are chosen such that the retention strength of the coil placed in the kidney is greater than the retention strength of the coil placed in the bladder. A retention strength of at least about 10 gram-force or more is desirable in many embodiments.


Some embodiments of stents according to the invention can have an outer diameter from about four to about nine French with lengths of from about ten to about thirty centimeters as measured between the coils. FIG. 11 shows an example of some suitable French sizes along with the size of the inner and outer diameters. Unless otherwise noted, the dimensions in FIG. 11 are in inches. The notation “O.D.” refers to outer diameter and the notation “I.D.” refers to inner diameter. In certain embodiments, stents with standard outer diameter sizes can have inner diameters (i.e., the diameter of a lumen) that are larger than standard inner diameters normally present in those standard outer diameters. This configuration facilitates passage of the stent over the guidewire and increases the drainage allowed by the stent. For example, a four French stent can have an inner diameter equivalent to that found in a 4.8 French stent to increase drainage and to facilitate a 0.35 inch and/or a 0.38 inch guidewire, and/or a five French stent can have an inner diameter equivalent to a six French stent to facilitate a 0.35 inch and/or a 0.38 inch guidewire and increase drainage.


The stent can have graduation marks and stent size imprinted on stent. For example, one marking pattern is shown in FIG. 9. This stent also has a slightly asymmetrical coil 15 which makes more than one revolution. This coil is the coil to be placed in the kidney (although in other embodiments, the asymmetrical coil can be the one to be placed in the bladder, or both coils). The taper of the renal coil is relatively long. Sizing information and marks about every 5 cm are used as an inking pattern. Two marks are used for 5 cm; three marks are used for 10 cm; four marks are used for 15 cm; and one thick mark is used to indicate the beginning of the bladder coil. Also, a radiopaque band can be included on some stents. Also, in certain embodiments of the invention, the renal coil retention strength can measure about 25-30 gram-force. The shaft and bladder coil can be softer, having a coil retention strength of about 14 gram-force. However, the shaft, or a portion thereof, may or may not be made from material(s) of the same durometer as either of the two coils (for example, to stiffen the shaft to facilitate placement of the stent).


In operation, the distal end of the stent 10 is inserted through the bladder 104 and ureter 102 into the kidney 100. For example, a medical professional inserts a guidewire (not shown) through the bladder 104, ureter 102 and kidney 100 of a patient. The stent 10 is placed over the guidewire, thereby uncurling the coils 12, 14 to the straightened position. The stent 10 slides along the guidewire, and the guidewire is sufficiently stiff to hold the coils 12, 14 in a straight configuration (e.g., the proximal coil in a straightened position 26, FIG. 1) while the guidewire is in the lumen of the stent 10. A pusher (optionally with a radiopaque band) that slides over the guidewire, behind the stent 10, abuts the end of the stent and is used to push the stent 10 over the guidewire. The radiopaque band, if used, allows a medical professional to view the pusher on a fluoroscope, particularly where it abuts the stent, using x-rays. Additionally, if the stent 10 is radiopaque, placement of the stent in the patient can be confirmed by viewing the stent on a fluoroscope. Once at least a portion of the second section 20 is positioned within the kidney 100, the guidewire is withdrawn. If a pusher is used, the pusher holds the stent in place while the guidewire is removed. The shape-memory material from which second coil 12 is constructed allows the second section 20 in a straightened position to return to its coiled shape in the kidney 100 once the guidewire is withdrawn. A similar re-coiling of the first coil 14 also occurs in the bladder 104 when the guidewire is withdrawn from that area of the stent 10. Thus, the “hard” coil 12 is placed in the kidney 100, and the “soft” coil 14 is placed in the bladder 104. Stents can be provided as a kit with a guidewire and/or a pusher.


The tapered tip on the second coil 14 (the renal coil) can facilitate inserting the stent through the passages of the patient's body. Additionally, a medical professional can use the suture 18 to reposition the stent (by pulling on it) when inserting the stent, and the medical professional can use the suture 18 to remove the stent from the patient. For example, the medical professional either leaves the suture inside the patient's body or leaves the end of the suture outside the body. When the stent 10 is to be removed, the medical professional pulls on the suture 18, removing the stent. However, the suture 18 does not have to be used to remove the stent 10.


When placed in a patient's body, stents according to the invention may soften slightly, as might many thermoplastic materials when exposed to elevated temperatures, for example, but without limitation, by about 30% or less, or about 20% or less, or about 10% or less, or about 5% or less. However, such softening is not substantial. Softening can be measured by methods known in the art. For example, the ASTM test method described herein may be adapted to determine if coils soften by determining if body temperature conditions cause a decrease in retention strength relative to room temperature conditions. However, other methods may be used.


An alternative method to straighten the coil 12 of the second section 20 is to produce relative movement between a straightening device (e.g., a sheath) and second section 20, such that the straightening device moves distally relative to the second section 20, thereby uncurling the coil 12 to a straightened position. Once at least some portion of the second section 20 is positioned within the kidney 100, the straightening device is removed. The second section 20 is constructed from a shape-memory material. Thus, once the straightening device is withdrawn, the coil 12 in the straightened position returns to its coiled shape. A similar re-coiling of the first coil 14 also occurs when the straightening device is withdrawn from that area of the stent 10. Other modes of inserting and/or straightening a device also are useful.


Variations, modifications, and other implementations of what is described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. Accordingly, the invention is to be defined not only by the preceding illustrative description.

Claims
  • 1. A medical stent comprising: a proximal end portion defining a lumen and including a first retention structure, the proximal end portion constructed from at least a first material having a first durometer value, the first retention structure includes a coil offset from a longitudinal axis of the medical stent, the proximal end portion defining a first opening and a second opening, the first opening and the second opening being in fluid communication with the lumen defined by the proximal end portion;a suture extending through the first opening and the second opening and being configured to facilitate the removal of the medical stent from a body of a patient;a distal end portion defining a lumen and including a second retention structure, the distal end portion constructed from at least a second material having a second durometer value, the second durometer value being greater than the first durometer value; anda central portion disposed between the proximal end portion and the distal end portion, the central portion defining a lumen in fluid communication with the lumen of the proximal end portion and the lumen of the distal end portion, the lumen of the central portion defining a longitudinal axis, the central portion constructed from the first material and the second material, the first material and the second material being co-extruded within the central portion such that the first material and the second material are distinct from each other and arranged substantially asymmetrically within a plane normal to the longitudinal axis.
  • 2. The medical stent of claim 1, wherein the relative amounts of the first material and the second material within the central portion vary non-linearly within a plane parallel to the longitudinal axis.
  • 3. The medical stent of claim 1, wherein an outer surface of the central portion smoothly transitions to an outer surface of the proximal end portion and an outer surface of the distal end portion.
  • 4. The medical stent of claim 1, wherein an inner diameter of the central portion, an inner diameter of the proximal end portion adjacent the central portion and an inner diameter of the distal end portion adjacent the central portion are substantially constant.
  • 5. The medical stent of claim 1, wherein the proximal end portion is devoid of the second material and the distal end portion is devoid of the first material.
  • 6. The medical stent of claim 1, wherein the first material includes ethylene vinyl acetate.
  • 7. The medical stent of claim 1, wherein the first material has a durometer value of about 70 to about 90 on a Shore A scale.
  • 8. The medical stent of claim 1, wherein at least one of the proximal end portion, the distal end portion, and the central portion includes a lubricant.
  • 9. The medical stent of claim 8, wherein the lubricant is a hydrophilic material.
  • 10. The medical stent of claim 8, wherein the lubricant is disposed about an outer surface of the proximal end portion and an outer surface of the distal end portion.
  • 11. The medical stent of claim 8, wherein the lubricant is covers at least a portion of each of the proximal end portion, the distal end portion, and the central portion.
  • 12. The medical stent of claim 8, wherein the lubricant covers the entire medical stent.
  • 13. The medical stent of claim 1, wherein a proximal end of the first retention structure extends in a direction parallel to longitudinal axis defined by the medical stent.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 10/765,382, filed Jan. 27, 2004, entitled “Medical Stent and Related Methods,” now U.S. Pat. No. 7,291,180, which is a continuation of U.S. patent application Ser. No. 10/032,712, filed Oct. 24, 2001, now U.S. Pat. No. 6,719,804, which claims priority to and the benefit of U.S. Patent Application No. 60/280,809, filed on Apr. 2, 2001, all of which are incorporated herein by reference in their entirety.

US Referenced Citations (361)
Number Name Date Kind
191775 Parsons Jun 1877 A
256590 Pfarre Apr 1882 A
386603 Parsons Jul 1888 A
559620 Shearer May 1896 A
1211928 Fisher Jan 1917 A
2257369 Davis Sep 1941 A
3087493 Schossow Apr 1963 A
3314430 Alley et al. Apr 1967 A
3359974 Khalil Dec 1967 A
3394705 Abramson Jul 1968 A
3437088 Bielinski Apr 1969 A
3485234 Stevens Dec 1969 A
3593713 Bogoff et al. Jul 1971 A
3612050 Sheridan Oct 1971 A
3633579 Alley et al. Jan 1972 A
3726281 Norton et al. Apr 1973 A
3746003 Blake et al. Jul 1973 A
3788326 Jacobs Jan 1974 A
3828767 Spiroff Aug 1974 A
3902492 Greenhalgh Sep 1975 A
3906954 Baehr et al. Sep 1975 A
3920023 Dye et al. Nov 1975 A
3995623 Blake et al. Dec 1976 A
4004588 Alexander Jan 1977 A
4037599 Raulerson Jul 1977 A
4065264 Lewin Dec 1977 A
4069814 Clemens Jan 1978 A
4096860 McLaughlin Jun 1978 A
4099528 Sorenson et al. Jul 1978 A
4100246 Frisch Jul 1978 A
4129129 Amrine Dec 1978 A
4134402 Marhurkar Jan 1979 A
4138288 Lewin Feb 1979 A
4138457 Rudd et al. Feb 1979 A
4144884 Tersteegen et al. Mar 1979 A
4149535 Volder Apr 1979 A
4168703 Kenigsberg Sep 1979 A
4173981 Mortensen Nov 1979 A
4180068 Jacobsen et al. Dec 1979 A
4182739 Curtis Jan 1980 A
4183961 Curtis Jan 1980 A
4202332 Tersteegen et al. May 1980 A
4203436 Grimsrud May 1980 A
4204541 Kapitanov May 1980 A
4212304 Finney Jul 1980 A
4217895 Sagae et al. Aug 1980 A
4223676 Wuchinich et al. Sep 1980 A
4236520 Anderson Dec 1980 A
4239042 Asai Dec 1980 A
4248234 Assenza et al. Feb 1981 A
4257416 Prager Mar 1981 A
4270535 Bogue et al. Jun 1981 A
4307723 Finney Dec 1981 A
4327722 Groshong et al. May 1982 A
4334327 Lyman et al. Jun 1982 A
4385631 Uthmann May 1983 A
4385635 Ruiz May 1983 A
4403983 Edelman et al. Sep 1983 A
4405313 Sisley et al. Sep 1983 A
4405314 Cope Sep 1983 A
4406656 Hattler et al. Sep 1983 A
4413989 Schjeldahl et al. Nov 1983 A
4419094 Patel Dec 1983 A
D272651 Mahurkar Feb 1984 S
4443333 Mahurkar Apr 1984 A
4451252 Martin May 1984 A
4456000 Schjeldahl et al. Jun 1984 A
4484585 Baier Nov 1984 A
4493696 Uldall Jan 1985 A
4504264 Kelman Mar 1985 A
RE31873 Howes Apr 1985 E
4531933 Norton et al. Jul 1985 A
4540402 Aigner Sep 1985 A
4543087 Sommercorn et al. Sep 1985 A
4553959 Hickey et al. Nov 1985 A
4559046 Groshong et al. Dec 1985 A
4563170 Aigner Jan 1986 A
4563181 Wijayarathna et al. Jan 1986 A
4568329 Mahurkar Feb 1986 A
4568338 Todd Feb 1986 A
4581012 Brown et al. Apr 1986 A
4583968 Mahurkar Apr 1986 A
4596548 DeVries et al. Jun 1986 A
4601697 Mammolenti et al. Jul 1986 A
4601701 Mueller, Jr. Jul 1986 A
4608993 Albert Sep 1986 A
4610657 Densow Sep 1986 A
4619643 Bai Oct 1986 A
4623327 Marhurkar Nov 1986 A
4626240 Edelman et al. Dec 1986 A
4641652 Hutterer et al. Feb 1987 A
4643711 Bates Feb 1987 A
4643716 Drach Feb 1987 A
4648865 Aigner Mar 1987 A
4655771 Wallsten Apr 1987 A
4661396 Andorf et al. Apr 1987 A
4662404 LeVeen et al. May 1987 A
4666426 Aigner May 1987 A
4671795 Mulchin Jun 1987 A
4675004 Hadford et al. Jun 1987 A
4682978 Martin Jul 1987 A
4687471 Twardowski et al. Aug 1987 A
4692141 Marhurkar Sep 1987 A
4694838 Wijayarthna et al. Sep 1987 A
4713049 Carter Dec 1987 A
4722725 Sawyer et al. Feb 1988 A
4732152 Wallstën et al. Mar 1988 A
4737146 Amaki et al. Apr 1988 A
4738667 Galloway Apr 1988 A
4739768 Engelson Apr 1988 A
4747840 Ladika et al. May 1988 A
4753640 Nichols et al. Jun 1988 A
4755176 Patel Jul 1988 A
4769005 Ginsburg et al. Sep 1988 A
4770652 Marhurkar Sep 1988 A
4772268 Bates Sep 1988 A
4773432 Rydell Sep 1988 A
4775371 Mueller, Jr. Oct 1988 A
4776841 Catalano Oct 1988 A
4787884 Goldberg Nov 1988 A
4790809 Kuntz Dec 1988 A
4790810 Pugh, Jr. et al. Dec 1988 A
4795439 Guest Jan 1989 A
4808155 Marhurkar Feb 1989 A
4809710 Williamson Mar 1989 A
4813429 Eshel et al. Mar 1989 A
4813925 Anderson, Jr. et al. Mar 1989 A
4820262 Finney Apr 1989 A
4822345 Danforth Apr 1989 A
4838881 Bennett Jun 1989 A
4842582 Marhurkar Jun 1989 A
4842590 Tanabe et al. Jun 1989 A
4846791 Hattler et al. Jul 1989 A
4846814 Ruiz Jul 1989 A
4863442 DeMello et al. Sep 1989 A
4874360 Goldberg et al. Oct 1989 A
4887996 Bengmark Dec 1989 A
4888146 Dandeneau Dec 1989 A
4894057 Howes Jan 1990 A
4895561 Marhurkar Jan 1990 A
4913683 Gregory Apr 1990 A
4931037 Wetterman Jun 1990 A
4950228 Knapp, Jr. et al. Aug 1990 A
4954126 Wallsten Sep 1990 A
4960409 Catalano Oct 1990 A
4960411 Buchbinder Oct 1990 A
4961809 Martin Oct 1990 A
4963129 Rusch Oct 1990 A
4973301 Nissenkorn Nov 1990 A
4976690 Solar et al. Dec 1990 A
4978341 Niederhauser Dec 1990 A
4981482 Ichikawa Jan 1991 A
4985022 Fearnot et al. Jan 1991 A
4986814 Burney et al. Jan 1991 A
4990133 Solazzo Feb 1991 A
4994071 MacGregor Feb 1991 A
4995863 Nichols et al. Feb 1991 A
4995865 Gahara et al. Feb 1991 A
4995868 Brazier Feb 1991 A
4998919 Schnepp-Pesch et al. Mar 1991 A
5004456 Botterbusch et al. Apr 1991 A
5009636 Wortley et al. Apr 1991 A
5013296 Buckberg et al. May 1991 A
5019102 Hoene May 1991 A
5026377 Burton et al. Jun 1991 A
5029580 Radford et al. Jul 1991 A
5041083 Tsuchida et al. Aug 1991 A
5053004 Markel et al. Oct 1991 A
5053023 Martin Oct 1991 A
5057073 Martin Oct 1991 A
5061275 Wallstén et al. Oct 1991 A
5078720 Burton et al. Jan 1992 A
5085629 Goldberg et al. Feb 1992 A
5116309 Coll May 1992 A
5124127 Jones et al. Jun 1992 A
5129910 Phan et al. Jul 1992 A
5135487 Morrill et al. Aug 1992 A
5135599 Martin et al. Aug 1992 A
5141502 Macaluso, Jr. Aug 1992 A
5147370 McNamara et al. Sep 1992 A
5149330 Brightbill Sep 1992 A
5156592 Martin et al. Oct 1992 A
5156596 Balbierz et al. Oct 1992 A
5156857 Wang et al. Oct 1992 A
5160325 Nichols et al. Nov 1992 A
5167623 Cianci et al. Dec 1992 A
5171216 Dasse et al. Dec 1992 A
5176625 Brisson Jan 1993 A
5176626 Soehendra Jan 1993 A
5178803 Tsuchida et al. Jan 1993 A
5188593 Martin Feb 1993 A
5190520 Fenton, Jr. et al. Mar 1993 A
5195962 Martin et al. Mar 1993 A
5197951 Marhurkar Mar 1993 A
5207648 Gross May 1993 A
5209723 Twardowski et al. May 1993 A
5211627 William May 1993 A
5221253 Coll Jun 1993 A
5221255 Marhurkar et al. Jun 1993 A
5221256 Marhurkar Jun 1993 A
5222949 Kaldany Jun 1993 A
5224953 Morgentalker Jul 1993 A
5234663 Jones et al. Aug 1993 A
5240677 Jones et al. Aug 1993 A
5242395 Maglinte Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5250038 Melker et al. Oct 1993 A
5261879 Brill Nov 1993 A
5269802 Garber Dec 1993 A
5275597 Higgins et al. Jan 1994 A
5279560 Morrill et al. Jan 1994 A
5282784 Willard Feb 1994 A
5290585 Elton Mar 1994 A
5292305 Boudewijn et al. Mar 1994 A
5292321 Lee Mar 1994 A
5295954 Sachse Mar 1994 A
5308322 Tennican et al. May 1994 A
5308342 Sepetka et al. May 1994 A
5318532 Frassica Jun 1994 A
5324274 Martin Jun 1994 A
5330449 Prichard et al. Jul 1994 A
5338311 Marhurkar Aug 1994 A
5342301 Saab Aug 1994 A
5342386 Trotta Aug 1994 A
5342387 Summers Aug 1994 A
5346467 Coll Sep 1994 A
5346471 Raulerson Sep 1994 A
5348536 Young et al. Sep 1994 A
5354263 Coll Oct 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5356423 Tihon et al. Oct 1994 A
5356424 Buzerak et al. Oct 1994 A
5358689 Jones et al. Oct 1994 A
5360397 Pinchuk Nov 1994 A
5364340 Coll Nov 1994 A
5364344 Beattie et al. Nov 1994 A
5366464 Belknap Nov 1994 A
5372600 Beyar et al. Dec 1994 A
5374245 Marhurkar Dec 1994 A
5378230 Marhurkar Jan 1995 A
5380270 Ahmadzadeh Jan 1995 A
5380276 Miller et al. Jan 1995 A
5383928 Scott et al. Jan 1995 A
5391196 Devonec Feb 1995 A
5395316 Martin Mar 1995 A
5399172 Martin et al. Mar 1995 A
5401257 Chevalier, Jr. et al. Mar 1995 A
5403291 Abrahamson Apr 1995 A
5405320 Twardowski et al. Apr 1995 A
5405329 Durand Apr 1995 A
5405341 Martin Apr 1995 A
5405380 Gianotti et al. Apr 1995 A
5411490 Tennican et al. May 1995 A
5440327 Stevens Aug 1995 A
5445624 Jimenez Aug 1995 A
5449372 Schmaltz et al. Sep 1995 A
5451206 Young Sep 1995 A
5464398 Haindl Nov 1995 A
5470322 Horzewski et al. Nov 1995 A
5472417 Martin et al. Dec 1995 A
5472432 Martin Dec 1995 A
5472435 Sutton Dec 1995 A
5480380 Martin Jan 1996 A
5484424 Cottenceau et al. Jan 1996 A
5486159 Maharkur Jan 1996 A
5489278 Abrahamson Feb 1996 A
5509897 Twardowski et al. Apr 1996 A
5514100 Marhurkar May 1996 A
5514176 Bosley, Jr. May 1996 A
5514178 Torchio May 1996 A
5520697 Lindenberg et al. May 1996 A
5522807 Luther Jun 1996 A
5527337 Stack et al. Jun 1996 A
5531741 Barbacci Jul 1996 A
5533985 Wang Jul 1996 A
5540713 Schnepp-Pesch et al. Jul 1996 A
5542937 Chee et al. Aug 1996 A
5553665 Gentry Sep 1996 A
5554136 Luther Sep 1996 A
5556390 Hicks Sep 1996 A
5562641 Flomenblit et al. Oct 1996 A
5569182 Twardowski et al. Oct 1996 A
5569184 Crocker et al. Oct 1996 A
5569195 Saab Oct 1996 A
5569215 Crocker Oct 1996 A
5569218 Berg Oct 1996 A
5571093 Cruz et al. Nov 1996 A
5573508 Thornton Nov 1996 A
5599291 Balbierz et al. Feb 1997 A
5601538 Deem Feb 1997 A
5613980 Chauhan Mar 1997 A
5622665 Wang Apr 1997 A
5624413 Markel et al. Apr 1997 A
5630794 Lax et al. May 1997 A
5632734 Galel et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5643222 Marhurkar Jul 1997 A
5647843 Mesrobian et al. Jul 1997 A
5649909 Cornelius Jul 1997 A
5653689 Buelna et al. Aug 1997 A
5658263 Dang et al. Aug 1997 A
5667486 Mikulich et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5676697 McDonald Oct 1997 A
5681274 Perkins et al. Oct 1997 A
5683640 Miller et al. Nov 1997 A
5685862 Marhurkar Nov 1997 A
5685867 Twardowski et al. Nov 1997 A
5695479 Jagpal Dec 1997 A
5695482 Kaldany Dec 1997 A
5695789 Harris Dec 1997 A
5707386 Schnepp-Pesch et al. Jan 1998 A
5709874 Hanson et al. Jan 1998 A
5718862 Thompson Feb 1998 A
5725814 Harris Mar 1998 A
5730733 Mortier et al. Mar 1998 A
5755774 Pinchuk May 1998 A
5762630 Bley et al. Jun 1998 A
5766209 Devonec Jun 1998 A
5769868 Yock Jun 1998 A
5772641 Wilson Jun 1998 A
5776161 Globerman Jul 1998 A
5791036 Goodin et al. Aug 1998 A
5792105 Lin et al. Aug 1998 A
5792124 Horrigan et al. Aug 1998 A
5792400 Talja et al. Aug 1998 A
5795319 Ali Aug 1998 A
5795326 Simán Aug 1998 A
5830179 Mikus et al. Nov 1998 A
5830184 Basta Nov 1998 A
5830196 Hicks Nov 1998 A
5836925 Soltesz Nov 1998 A
5843028 Weaver et al. Dec 1998 A
5843175 Frantzen Dec 1998 A
5851203 van Muiden Dec 1998 A
5860999 Schnepp-Pesch et al. Jan 1999 A
5865815 Tihon Feb 1999 A
5876417 Devonec et al. Mar 1999 A
5895378 Nita Apr 1999 A
5897537 Berg et al. Apr 1999 A
5899891 Racz May 1999 A
5899892 Mortier et al. May 1999 A
5906640 Penn et al. May 1999 A
5911715 Berg et al. Jun 1999 A
5928217 Mikus et al. Jul 1999 A
5947939 Mortier et al. Sep 1999 A
5961511 Mortier et al. Oct 1999 A
5964744 Balbierz et al. Oct 1999 A
5964771 Beyar et al. Oct 1999 A
5976120 Chow et al. Nov 1999 A
5980505 Wilson Nov 1999 A
5984907 McGee et al. Nov 1999 A
6007478 Siess et al. Dec 1999 A
6019789 Dinh et al. Feb 2000 A
6033413 Mikus et al. Mar 2000 A
6135992 Wang Oct 2000 A
6139536 Mikus et al. Oct 2000 A
6620202 Bottcher et al. Sep 2003 B2
6719804 St. Pierre Apr 2004 B2
7291180 St. Pierre Nov 2007 B2
20020143389 St. Pierre Oct 2002 A1
Foreign Referenced Citations (55)
Number Date Country
1092927 Jan 1981 CA
1150122 Jul 1983 CA
1167727 May 1984 CA
1193508 Sep 1985 CA
1219785 Mar 1987 CA
1225299 Nov 1987 CA
2259865 Jun 1974 DE
3112762 Jan 1983 DE
35 17 813 Nov 1986 DE
37 40 288 Apr 1989 DE
41 03 573 Aug 1992 DE
41 34 030 Apr 1993 DE
93 14 585.3 Jan 1994 DE
0036642 Sep 1981 EP
0079719 May 1983 EP
0101890 Mar 1984 EP
0101890 Mar 1984 EP
0144525 Jun 1985 EP
0168136 Jan 1986 EP
0183421 Jun 1986 EP
0 326 908 Aug 1989 EP
0333308 Sep 1989 EP
0183421 Apr 1990 EP
0386408 Sep 1990 EP
0490459 Jun 1992 EP
0490459 Jun 1992 EP
0554722 Aug 1993 EP
0 876 803 Nov 1998 EP
0 916 362 May 1999 EP
1285953 Jan 1962 FR
1508959 Dec 1967 FR
2297640 Aug 1976 FR
2530958 Feb 1984 FR
2 611 486 Sep 1988 FR
2017499 Oct 1979 GB
2156220 Oct 1985 GB
2235384 Mar 1991 GB
57-90150 Jun 1982 JP
62-20830 Jan 1987 JP
WO 8404043 Oct 1984 WO
WO 9526763 Oct 1995 WO
WO 9528982 Nov 1995 WO
WO 9529051 Nov 1995 WO
WO 9535130 Dec 1995 WO
WO 9710858 Mar 1997 WO
WO 9717094 May 1997 WO
WO 9737699 Oct 1997 WO
WO 9737718 Oct 1997 WO
WO 9739788 Oct 1997 WO
WO 9822159 May 1998 WO
WO 9843695 Oct 1998 WO
WO 9856313 Dec 1998 WO
WO 9939661 Aug 1999 WO
WO 9949811 Oct 1999 WO
WO 02078778 Oct 2002 WO
Related Publications (1)
Number Date Country
20080086215 A1 Apr 2008 US
Provisional Applications (1)
Number Date Country
60280809 Apr 2001 US
Continuations (2)
Number Date Country
Parent 10765382 Jan 2004 US
Child 11935179 US
Parent 10032712 Oct 2001 US
Child 10765382 US